Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT: NCT05838625 · COMPLETED

NCT IDNCT05838625
StatusCOMPLETED
Start Date2023-03-31
Completion2025-07-23
SponsorClick Therapeutics, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.

Frequently Asked Questions

What is Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia?

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia is a clinical trial registered under NCT05838625. Current status: COMPLETED.

What is the status of NCT05838625?

The current status of NCT05838625 (Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia) is: COMPLETED.

When did Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia start?

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia started on 2023-03-31.

Related Devices

K254038Motivista (CT-155)Click Therapeutics, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑